logo
‘Hold on to me.' Victim saved fiancee in violent tornado that hit Central KY

‘Hold on to me.' Victim saved fiancee in violent tornado that hit Central KY

Yahoo01-06-2025
When Ronnie Hill and his fiance Tonya Orberson heard a tornado with its 115 mph winds barreling down on their Washington County home right around 7 a.m. Friday morning, they raced to the laundry room.
Ronnie laid of top of Tonya and told her, 'No matter what, you hold on to me.'
'She said all of a sudden, they just all went up in the air. Her and Ronnie were still holding hands, Lashanna Gibson, who is Orberson's daughter, told the Herald-Leader Saturday.
'She was screaming, and Ronnie was saying, 'Do not let go.''
The raging tornado lifted and destroyed their home, sending the couple flying.
'They ended up beside the pond. They were still laying right beside of each other whenever they hit the ground, Gibson said.
'Mom said she woke up and she was hollering for him. He wouldn't answer her. She looked over and she could tell that he was already gone. '
'He protected her until his last breath,' Gibson said. 'He was a true hero.'
The 48-year-old Ronnie, the only person who died in Friday's EF2 tornado that struck Washington County, and Tonya got engaged to be married in late April.
They hadn't yet set a wedding date.
Tonya was at the University of Kentucky Chandler Hospital Saturday with a broken back, a broken arm, a dislocated elbow and a large cut on her head, Gibson said.
Jack Coleman, a former state lawmaker and father of Lt. Gov. Jacqueline Coleman, said Ronnie worked for him as a contractor.
Coleman was the project manager during the construction of All Together Recovery, a 50-bed residential addiction treatment center for men in Danville.
Coleman worked with Ronnie, who continued to oversee maintenance and remodeling at the center's apartments after construction was completed.
'He could do anything,' he said Saturday.
'We hired Ronnie last summer. He was wonderful. He had just come out of recovery. He had a powerful testimony. He gave people hope that they could be successful in recovery, too.
'He was really a goodhearted fellow,' Coleman added. 'He wanted to help people.'
Coleman said when he learned on Friday that Ronnie had died, 'I just couldn't believe it.'
Mark La Palme, a consultant at the All Together Recovery Center, said the men in recovery who lived in the apartments where Ronnie was a maintenance man and remodeler, cried when they heard he died.
'He had a ton of past to overcome, but he did it,' said LaPalme.
'He did it with grace and mercy and style. Ronnie would literally have given you his last penny, his last gallon of gas, the shirt off of his back.
'That's the kind of guy that Ronnie Hill was.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

More than 1,000 pets available at Fort Worth's Mega Adoption Event
More than 1,000 pets available at Fort Worth's Mega Adoption Event

CBS News

time6 minutes ago

  • CBS News

More than 1,000 pets available at Fort Worth's Mega Adoption Event

Animals from about two dozen regional shelters and rescue groups wait for their "furever" families at Fort Worth's Mega Adoption Event this weekend. This comes as local shelters experience historic overcrowding. A long line of animal lovers anxiously awaited to meet adoptable pets on Sunday morning at the Amon G. Carter, Jr. Exhibits Hall. More than 1,000 animals from more than 20 shelters and rescues waited to meet their prospective pet parents. That includes both dogs and puppies, as well as cats and kittens. The event features animals of all shapes and sizes, as well as purebred pets. Several North Texas shelters have had to pause owner surrenders this year due to overcrowding. "All shelters across North Texas have been at capacity or over capacity for such a long time, so by adopting a pet, you're actually in essence saving two lives. That's the life of the pet you just adopted, and you're opening critical kennel space," said Humane Society of North Texas senior director Cassie Davidson. "On a day-to-day basis, we do operate at 90 to 100% or above capacity. What that looks like is it's animals that are in our shelter for longer than we would like. That can lead to some behavioral issues, and then have to mitigate or manage," Fort Worth Animal Care & Control supervisor Anastasia Ramset said. The Mega Adoption Event continues through 4 p.m. Sunday, Aug. 17. If you can't make it out to the event, you can adopt a pet at a shelter. Adoption fees are waived this month at Fort Worth Animal Care and Control and many other North Texas shelters for the Clear the Shelters program.

Powerball ticket worth $80,000 sold in California
Powerball ticket worth $80,000 sold in California

Yahoo

time25 minutes ago

  • Yahoo

Powerball ticket worth $80,000 sold in California

The Brief No one got the jackpot in the Saturday, Aug. 16 drawing for the top prize of $565 million. The following were the winning numbers for the Aug. 16 drawing: 23, 40, 49, 65, 69. PB: 23 LOS ANGELES - Feeling lucky? As the nation awaits the winner of the $600 million Powerball lottery jackpot, someone in California may be $80,000 richer. What we know According to California Lottery's website on Saturday night, a ticket worth $80,504 was sold within the state. This comes as a drawing was held for the then-jackpot of $565 million. Below were the winning numbers for the Aug. 16 drawing – which apparently no one got all six numbers: 23, 40, 49, 65, 69. PB: 23 The drawing for the $600 million jackpot will be held on Monday, August 18 at 8 p.m. PT. HOW MUCH DO YOU WIN AFTER TAXES? There are 600 millions reasons to dream, especially what you would do with the jackpot money. However, one thing all lottery winners have to take into account is the fact that their prizes will be taxed. So how much do you really get after taxes? It depends on a couple of factors: do you have to pay state taxes where you live? Will you take the lump sum payment or the annuity payout? According to Mega Millions' website, those electing to take the annuity option get one immediate payment followed by 29 annual payments. Powerball follows an identical process for paying out its jackpot winners. RELATED: Powerball payout calculator: How much would you get after taxes if you won? This story was reported from Los Angeles. The Source This report used information provided by the California Lottery and Powerball. Solve the daily Crossword

1 Beaten-Down Stock That Could Soar by the End of the Year
1 Beaten-Down Stock That Could Soar by the End of the Year

Yahoo

time29 minutes ago

  • Yahoo

1 Beaten-Down Stock That Could Soar by the End of the Year

Key Points Viking's leading weight management candidate is being investigated in two formulations. The stock could soar later this year, provided the oral version aces phase 2 studies. Viking Therapeutics is somewhat risky, but it also has significant upside potential. 10 stocks we like better than Viking Therapeutics › Some smaller drugmakers choose to develop medicines for diseases for which there are no therapeutic options. This allows them to avoid direct competition from larger pharmaceutical companies. That's not exactly the strategy Viking Therapeutics (NASDAQ: VKTX) chose. The mid-cap biotech is working on weight loss therapies, an increasingly competitive market dominated by Eli Lilly (NYSE: LLY) and Novo Nordisk, as well as numerous other well-established players in the industry seeking to enter the space. Going up against these giants is no small challenge, but Viking is, so far, holding its own. And if it can play its cards right, its stock could soar by the end of the year and go on to generate strong returns from then on out. Here's more on Viking Therapeutics. Eli Lilly's setback creates an opportunity Viking Therapeutics' shares soared last year following the release of strong phase 2 data for its subcutaneous weight management candidate, VK2735. The stock has declined significantly since that milestone, although it's not due to anything Viking did wrong. Broader market volatility, combined with long-term shareholders taking some profits, is likely responsible for the stock's 40% drop over the trailing-12-month period. VK2735 is currently in phase 3 studies, but Viking is also developing an oral version of the medicine, which is in phase 2 clinical trials. There is a race to develop a highly effective oral GLP-1 anti-obesity therapy, since the current market leaders are administered via subcutaneous injection. If Viking Therapeutics' oral candidate can impress in mid-stage studies, the stock could soar. That's especially the case since Eli Lilly's investigational oral GLP-1 medicine, orforglipron, failed to perform as well as expected in a phase 3 study in obese or overweight patients who didn't have diabetes. Orforglipron led to a mean weight loss of 12.4% in a 72-week study, which wasn't as impressive as the market wanted. This result paled in comparison to Lilly's injectable Zepbound, which led to an average weight loss of 20.2% in a phase 3 study. Viking Therapeutics' shares jumped on the pharmaceutical giant's bad news, but there's plenty of upside left if its oral weight loss candidate meets Wall Street's expectations. It's best to start small Eli Lilly is perceived as the leader in the weight management market. The company's continued dominance in this field was likely somewhat baked into investor expectations, requiring it to deliver outstanding clinical trial results to justify its share price. Viking is a much smaller drugmaker than Lilly, so the market will likely have lower expectations for its data readouts for VK2735. Viking also has several other exciting candidates. The company is working on a drug called VK2809, a potential therapy for metabolic dysfunction-associated steatohepatitis (MASH), which produced solid results in phase 2 studies. There is a vast unmet need in MASH, considering several million people have the disease, yet the U.S. Food and Drug Administration has approved just a single medication for it. Elsewhere, Viking has a next-gen anti-obesity candidate that could soon start human clinical trials. The company has a lot going on, and if VK2735-related developments remain strong through the end of the year, the stock could soar. However, Viking -- like any clinical-stage biotech company -- is a somewhat risky bet. On the one hand, it has generated strong mid-stage data for two separate medicines that address high unmet needs. Its leading candidate, VK2735, has the potential to become a blockbuster; that's impressive. Even so, the stock will plummet if VK2735 encounters clinical setbacks. So, should you buy shares? In my view, it depends on your level of risk tolerance. Risk-averse investors should look elsewhere. If you're comfortable with a bit of volatility, you should seriously consider the stock; however, it would be wise to start by initiating a small position. If the data from the ongoing phase 2 study for oral VK2735 is good, it might be worth adding even more shares thereafter. Should you buy stock in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. 1 Beaten-Down Stock That Could Soar by the End of the Year was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store